Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Hodgkin Disease × Bendamustine Hydrochloride × Clear all

Phase

Status

Sponsor Class

OTHER 23 INDUSTRY 2 UNKNOWN 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 4 Lymphoma, Mantle-Cell 3 Lymphoma, Follicular 2 Multiple Myeloma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hodgkin Disease 1

Interventions

Doxorubicin 12 Bleomycin 10 Vincristine 9 Vinblastine 9 Prednisone 9 Etoposide 9 Cyclophosphamide 9 Radiotherapy 8 Filgrastim 8 Dacarbazine 6 Procarbazine 5 Granulocyte Colony-Stimulating Factor 5 Dexamethasone 5 Vinorelbine 4 Peripheral Blood Stem Cell Transplantation 4 Melphalan 4 Gemcitabine 4 Cytarabine 4 Cisplatin 4 Carmustine 4 etoposide phosphate 3 Mechlorethamine 3 Ifosfamide 3 ABVD protocol 3 indolepropanol phosphate 2 Whole-Body Irradiation 2 Positron Emission Tomography Computed Tomography 2 Podophyllotoxin 2 Nivolumab 2 Methotrexate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03615664 2025-01-16

BURGUND

Polish Lymphoma Research Group

Phase 2 Completed

Hodgkin Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡